A 2021 updated clinical practice guideline provided recommendations for prevention of oral mucositis in pediatric cancer patients, including the use of palifermin during hematopoietic stem cell transplant. A total of 12 pediatric randomized controlled trials (RCTs) investigated were included for analysis, and palifermin was observed to significantly reduce severe mucositis (risk ratio [RR] 0.81; 95% confidence interval [CI] 0.69 to 0.95), but did not significantly reduce any mucositis or total parenteral nutrition administration compared to no prophylaxis. Short-term adverse events observed with palifermin include rash, erythema, and white film coating of the tongue and mouth. One patient developed second malignancy (squamous cell carcinoma of the oral epithelium) in a patient with chronic graft-versus-host disease. Based on these findings, the authors make a strong recommendation against use of palifermin in pediatric patients due to its only modest effect on reducing severe mucositis with potential for adverse effects. [1]
A 2017 Cochrane meta-analysis was conducted to assess interventions for prevention of oral mucositis during cancer treatment. However, due to low amounts of data in children and insufficient sample sizes, the authors concluded there was no compelling evidence that a specific agent would benefit children, although no severe safety concerns were noted. Isolated studies of pediatric patients receiving palifermin or allogeneic stem cell transplants did not provide substantial findings from the meta-analysis. [2]